Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by PNC Financial Services Group Inc.

PNC Financial Services Group Inc. lifted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 51.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,225 shares of the company’s stock after buying an additional 5,885 shares during the period. PNC Financial Services Group Inc.’s holdings in Hims & Hers Health were worth $417,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Crewe Advisors LLC bought a new stake in shares of Hims & Hers Health during the fourth quarter valued at about $28,000. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares in the last quarter. US Bancorp DE increased its stake in shares of Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after acquiring an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in Hims & Hers Health during the fourth quarter worth approximately $48,000. 63.52% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Andrew Dudum sold 36,460 shares of the firm’s stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now directly owns 27,918 shares of the company’s stock, valued at $756,298.62. This trade represents a 56.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company’s stock, valued at $9,549,268.05. This represents a 2.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,015,547 shares of company stock worth $36,146,450. Company insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research analyst reports. Leerink Partners boosted their price target on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 25th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $24.00 to $39.00 and gave the stock a “hold” rating in a research note on Wednesday, February 26th. Citigroup reissued a “sell” rating and set a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Finally, Needham & Company LLC increased their price objective on Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $37.31.

Hims & Hers Health Stock Down 3.0 %

Shares of HIMS stock opened at $32.85 on Friday. The business has a fifty day simple moving average of $39.02 and a 200 day simple moving average of $28.55. The company has a market cap of $7.30 billion, a P/E ratio of 74.67 and a beta of 1.37. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.